Duration of androgen suppression in the treatment of prostate cancer

New England Journal of Medicine

Volumn 360, Issue 24, 2009, Pages 2516-2527

  Bolla, Michel ^a   De Reijke, Theodorus M ^b   Van Tienhoven, Geertjan ^b   Van Den Bergh, Alphonsus C M ^c   Oddens, Jorg ^d   Poortmans, Philip M P ^e   Gez, Eliahu ^h   Kil, Paul ^f   Akdas, Atif ⁱ   Soete, Guy ^j   Kariakine, Oleg ^l   Van Der Steen Banasik, Elsbietha M ^g   Musat, Elena ^k   Piérart, Marianne ^k   Mauer, Murielle E ^k   Collette, Laurence ^k  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^f CPRLab   (Netherlands)

^g Arnhems Radiotherapeutisch Instituut   (Netherlands)

^h RAMBAM MEDICAL CENTER   (Israel)

ⁱ MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^j UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^k EORTC DATA CENTER   (Belgium)

^l Medical Oncological Research Center ^*  (Russian Federation)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; TRIPTORELIN; ANILIDE; ANTIANDROGEN; DRUG DERIVATIVE; GONADORELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EXTERNAL BEAM RADIOTHERAPY; GYNECOMASTIA; HOT FLUSH; HUMAN; INCONTINENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEXUAL BEHAVIOR; SIDE EFFECT; TREATMENT DURATION; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FOLLOW UP; HEART DISEASE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NITRILES; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, CONFORMAL; TOSYL COMPOUNDS; TREATMENT FAILURE;

EID: 67149125847     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0810095     Document Type: Article

References (31)

1. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300. (Pubitemid 27318990)
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-106 (Pubitemid 34786197)
3. Hanks GE, Corn BW, Lee WR, et al. External beam irradiation of prostate cancer: conformal treatment techniques and outcomes for the 1990s. Cancer 1995;75:1972-1977
4. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-2504
5. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290 (Pubitemid 40470408)
6. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456 (Pubitemid 46630983)
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-164 (Pubitemid 40096612)
8. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-3983 (Pubitemid 46630747)
9. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585-591 (Pubitemid 351264352)
10. Union Internationale Contre le Cancer. UICC TNM classification of malignant tumors. 4th ed., 2nd revision. New York: Springer-Verlag, 1992.
11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
12. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy. Report 50. Bethesda, MD: ICRU, 1993.
13. Kouloulias VE, Giraud JY, Davis BJ, Dusurre A, Zurlo A, Bolla M. Quality assurance of the 22961 EORTC trial: a phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run. Radiother Oncol 2004;73:11-20. (Pubitemid 39304120)
14. National Cancer Institute of Canada Clinical Trials Group. Expanded common toxicity criteria. Kingston, ON: National Cancer Institute of Canada Clinical Trials Group, 1994:1-35.
15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346
16. Fayers P, Aaronson NK, Bjordal K, Curran D, Groenvold M. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: EORTC Publications, 2001.
17. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129 (Pubitemid 13146129)
18. Com-Nougue C, Rodary C, Patte C. How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma. Stat Med 1993;12:1353-1364 (Pubitemid 23230837)
19. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
20. Lin D, Wei L, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-572
21. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. 2nd ed. New York: John Wiley, 2002.
22. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144 (Pubitemid 28041591)
23. D'Amico AV. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol 2007;25:8-9. (Pubitemid 350003044)
24. Hwang IK, Shih WJ, DeCani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990;9:1439-1445
25. Bolla M, van Tienhoven G, de Reijke TM, et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT - results of the randomized EORTC phase III trial 22961. J Clin Oncol 2007;25:Suppl:238s. abstract.
26. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer. JAMA 2008;299:289-295
27. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-308
28. Bolla M, Collette L, Van Tienhoven G, et al. Ten-year update of long-term adjuvant androgen deprivation with gosereline in patients with locally advanced prostate cancer treated with radiotherapy: a phase III EORTC study. Int J Radiat Oncol Biol Phys 2008;72:Suppl 1:S30-S31. abstract.
29. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005;7:Suppl 5:S37-S43.
30. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-3757 (Pubitemid 32844788)
31. Lubeck DP, Grossfeld GD, Carroll PR. The effect of androgen deprivation therapy on health related quality of life in men with prostate cancer. Urology 2001;58:Suppl:94-100. (Pubitemid 32743420)